AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31475296
Drug: Sacubitril-valsartan (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril-valsartan (target dosage, 97/103 mg twice daily)
Trial: 31475296
Drug: Enalapril (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (target dosage, 10 mg twice daily)
Trial: 25752834
Drug: Rituximab treatment
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab treatment (single infusion)
Trial: 23339809
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) adherence within the first month
Trial: 23339809
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) adherence during 1-6 months
Trial: 23339809
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) adherence during 6-12 months
Trial: 23339809
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) adherence beyond one year
Trial: 19919396
Drug: Bupropion (BUP)
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion (BUP) 150-300 mg
Trial: 19919396
Drug: Bupropion combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion combined with transdermal nicotine (BUP+TN)
Trial: 19919396
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C) - no drugs
Trial: 16890574
Drug: Ritonavir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (300 mg twice daily for 2 days)
Trial: 15310632
Drug: iv fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: iv fentanyl 2 to 3 microg.kg(‐1), propofol 2 mg.kg(‐1), and rocuronium 0.3 to 0.5 mg.kg(‐1)
Trial: 11742191
Drug: Budesonide (6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (6, 9, or 18 mg daily)
Trial: 11742191
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (steroid pretreatment)
Trial: 8052507
Drug: 60 mg/kgbw
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kgbw Biltricide (Group 1)
Trial: 8052507
Drug: 40 mg/kgbw
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kgbw (Group 2) - 12 Biltricide, 10 Distocide
Trial: 1778089
Drug: Carbaryl lotion
RxNorm normalized name: carbaryl Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbaryl lotion
Trial: 3148130
Drug: Malathion solution
RxNorm normalized name: Malathion
DrugBank: Malathion (DB00772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Malathion solution
Trial: 3148130
Drug: Pyrethroid spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrethroid spray
Trial: 31037611
Drug: Chiglitazar 8
RxNorm normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiglitazar 8 mg
Trial: 31037611
Drug: Chiglitazar 16
RxNorm normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiglitazar 16 mg
Trial: 31037611
Drug: Chiglitazar 32
RxNorm normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiglitazar 32 mg
Trial: 31037611
Drug: Chiglitazar 24
RxNorm normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiglitazar 24 mg
Trial: 31037611
Drug: Chiglitazar 48
RxNorm normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiglitazar 48 mg
Trial: 31037611
Drug: Chiglitazar 72
RxNorm normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiglitazar 72 mg
Trial: 31037611
Drug: Chiglitazar 16
RxNorm normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiglitazar 16 mg (multiple doses)
Trial: 21691610
Drug: Non-platform-switched implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-platform-switched implants
Trial: 21691610
Drug: Implant platform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant platform 4.3 mm
Trial: 21691610
Drug: Implant platform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant platform 4.8 mm
Trial: 21691610
Drug: Implant platform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant platform 5.5 mm
Trial: 17585313
Drug: pegaptanib sodium
RxNorm normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegaptanib sodium (0.3, 1, and 3 mg)
Trial: 9185468
Drug: Preoperative 50
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative 50 mg flurbiprofen with standardized general anesthesia
Trial: 9185468
Drug: Conventional combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional combined epidural and general anesthesia with epidural administration of 0.25% bupivacaine 5‐8 ml and 0.1‐0.2 mg buprenorphine after surgery
Trial: 12766861
Drug: Flunarizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (10 mg daily)
Trial: 29722747
Drug: Cyclic natural
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic natural progesterone therapy
Trial: 27942208
Drug: Nebulized ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized ipratropium bromide (500 µg)/salbutamol (2.5 mg)
Trial: 24297940
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (3,000 mg/m2 every 12 hours by 3-hour infusion on days 1, 3, 5, and 7)
Trial: 24297940
Drug: Standard-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose cytarabine (100 mg/m2 per day by continuous infusion for 10 days)
Trial: 21395141
Drug: Citrate anticoagulation
RxNorm normalized name: ANTICOAGULANT CITRATE DEXTROSE
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citrate anticoagulation with 0.2% Prismocitrate 10/2 solution
Trial: 17478491
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 g i.v.) for 4 months
Trial: 17478491
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 g i.v.) for 4 months
Trial: 17478491
Drug: Placebo (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (first 4 months) followed by L-carnitine (2 g i.v.) for 4 months
Trial: 17478491
Drug: L-carnitine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (0.5 mM and 5 mM) pre-incubation before agonist stimulation
Trial: 10550151
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with ifosfamide 10 g/m², carboplatin 1200 mg/m², and etoposide 1200 mg/m² (ICE)
Trial: 10550151
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with ifosfamide, carboplatin, and etoposide (ICE)
Trial: 17825689
Drug: Titration group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration group: 1 tablet of tramadol/acetaminophen 37.5/325 mg QD and 1 placebo BID for 3 days, followed by 1 active tablet BID and 1 placebo QD for 4 days, followed by 1 active tablet TID for 7 days.
Trial: 17825689
Drug: Nontitration group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nontitration group: 1 tablet of combined tramadol 37.5 mg/acetaminophen 325 mg TID for 14 days.
Trial: 11176729
Drug: High-dose lisinopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lisinopril (35.0 or 32.5 mg OD)
Trial: 11176729
Drug: Low-dose lisinopril
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lisinopril (5.0 or 2.5 mg OD)
Trial: 11176729
Drug: Low-dose lisinopril
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lisinopril
Trial: 11176729
Drug: High-dose strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose strategy
Trial: 9506648
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control (no treatment)
Trial: 8155435
Drug: i.v. ketoprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketoprofen 200 mg followed by 12.5 mg h‐1 over 13 h
Trial: 8155435
Drug: extradural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: extradural morphine 4 mg
Trial: 3247565
Drug: Local injections
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injections of purified botulinum toxin type 'A'
Trial: 3247565
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution injected with the same method as botulinum toxin
Trial: 29698447
Drug: Celecoxib (absent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (absent aspirin)
Trial: 20521975
Drug: Red ginseng
RxNorm normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red ginseng extract powder (1 g) administered orally per week for 3 years
Trial: 20521975
Drug: Red ginseng
RxNorm normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red ginseng extract powder (1 g) administered orally per week for 3 years (male subgroup)
Trial: 17229323
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g alcohol (control)
Trial: 8942463
Drug: D-cycloserine at
RxNorm normalized name: D-(+)-cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine at 50 mg/day
Trial: 1653594
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg, increased to 80 mg if needed after 4 weeks
Trial: 1653594
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg, increased to 200 mg if needed after 4 weeks
Trial: 6354603
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment plus nimesulide (100 mg twice daily)
Trial: 6354603
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment plus placebo
Trial: 20961784
Drug: Pre-antiretroviral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-antiretroviral therapy
Trial: 17326029
Drug: Waterless alcohol-chlorhexidine
RxNorm normalized name: chlorhexidine / isopropyl alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waterless alcohol-chlorhexidine lotion
Trial: 16303295
Drug: salbutamol 600
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: salbutamol 600 microg (6 x 100 microg via metered-dose inhaler)
Trial: 11218985
Drug: 40 U
RxNorm normalized name: lipase 10440 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 U of intranasal elcatonin (ELC) 2 months ON, 1 month OFF
Trial: 6384285
Drug: Selenium sulfide
RxNorm normalized name: Selenium Sulfide
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selenium sulfide (2.5%) lotion applied daily for 10 minutes for 7 consecutive days
Trial: 27329037
Drug: 70g dark
RxNorm normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70g dark chocolate (150 mg epicatechin) with placebo capsules
Trial: 27329037
Drug: Pure epicatechin
RxNorm normalized name: epicatechin
DrugBank: Epicatechin (DB12039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure epicatechin capsules (2 × 50 mg epicatechin) with 75g white chocolate
Trial: 27329037
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules with 75g white chocolate (0 mg epicatechin)
Trial: 22607938
Drug: Topical ophthalmic
RxNorm normalized name: MIOTICS,TOPICAL OPHTHALMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ophthalmic tofacitinib 0.005% QD
Trial: 22607938
Drug: Topical ophthalmic
RxNorm normalized name: MIOTICS,TOPICAL OPHTHALMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ophthalmic tofacitinib 0.003% BID
Trial: 17031690
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine and IFN-alpha
Trial: 6749189
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both agents
Trial: 7733022
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg fluoxetine/d
Trial: 6128740
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg lorazepam orally 1 hour before induction of labour
Trial: 6128740
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no pre-induction medication)
Trial: 31850844
Drug: Methylphenidate (catecholamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (catecholamine transporter blocker)
Trial: 11996469
Drug: Oxaliplatin 85
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85 mg/m2 on day 1 and topotecan 1.5 mg/m2 on days 2-5
Trial: 11996469
Drug: Oxaliplatin 85
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85 mg/m2 on day 1 and topotecan 1.25 mg/m2 on days 2-5
Trial: 11996469
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxaliplatin and topotecan
Trial: 11996469
Drug: Oxaliplatin 85
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85 mg/m2 and topotecan 1.25 mg/m2
Trial: 24858755
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) followed by placement of Atridox gel (10% doxycycline hyclate)
Trial: 19628729
Drug: levodopa/carbidopa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa/carbidopa (100 mg/25 mg bid)
Trial: 19628729
Drug: rotigotine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rotigotine (initial dose 2 mg/24 h for 3 days, followed by 4 mg/24 h)
Trial: 19628729
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of levodopa/carbidopa and rotigotine
Trial: 15134155
Drug: FertilityBlend (nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FertilityBlend (nutritional supplement)
Trial: 10518174
Drug: Sertraline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline + Group Cognitive Behavior Therapy
Trial: 10518174
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavior Therapy
Trial: 7758060
Drug: Granisetron 1
RxNorm normalized name: granisetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 1 mg BID
Trial: 7758060
Drug: Granisetron 2
RxNorm normalized name: granisetron 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 2 mg BID
Trial: 448576
Drug: Indomethacin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.25 mg/kg)
Trial: 448576
Drug: Indomethacin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.3 mg/kg)
Trial: 7924757
Drug: Indomethacin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (all doses)
Trial: 27881011
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy combined with bevacizumab intraperitoneal (i.p.)
Trial: 27881011
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy combined with bevacizumab intravenous (i.v.)
Trial: 22628120
Drug: Amoxycillin clavulanate
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin clavulanate (22.5 mg/kg/dose, twice daily for 2 weeks)
Trial: 17887949
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day silymarin
Trial: 12231521
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2 (1 x 10(6) IU/m(2)/day s.c. for 90 days)
Trial: 12231521
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2 with intermediate pulse doses (6-12 x 10(6) IU/m(2)/day s.c. for 3 days every 14 days, maximum five pulses)
Trial: 12231521
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2 with or without intermediate pulse dose therapy
Trial: 12231521
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2 with intermediate pulse doses
Trial: 9824783
Drug: Ganciclovir 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir 1,000 mg six times a day
Trial: 9824783
Drug: Ganciclovir 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir 1,500 mg four times a day
Trial: 9824783
Drug: Ganciclovir 2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir 2,000 mg three times a day
Trial: 2789919
Drug: Timolol 20
RxNorm normalized name: timolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 20 mg (positive control)
Trial: 22860014
Drug: Dual blockade
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual blockade with enalapril (20 mg o.d.) and candesartan (16 mg o.d.)
Trial: 22860014
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with enalapril or candesartan
Trial: 3177010
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg bromocriptine
Trial: 18093337
Drug: Cognitive-behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior therapy (CBT) alone
Trial: 25931327
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements alone
Trial: 16227417
Drug: Spa resort
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa resort treatment
Trial: 10458255
Drug: Multilevel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multilevel treatment algorithm based on the Agency for Health Care Policy and Research Guidelines for Cancer Pain Management
Trial: 10458255
Drug: Standard‐practice pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard‐practice pain and symptom management therapies
Trial: 7842187
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (mean 10.1 mg daily)
Trial: 7842187
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (15 mg daily for 7 days)
Trial: 7842187
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone (500 micrograms twice daily for 7 days)
Trial: 7842187
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (not taking oral steroids)
Trial: 2145871
Drug: UK 69,578
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK 69,578 (10 mg/kg)
Trial: 2145871
Drug: UK 69,578
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK 69,578 (0.025 to 10.0 mg/kg)
Trial: 28869786
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg dose of lorazepam
Trial: 28869786
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg dose of lorazepam
Trial: 28869786
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg dose of lorazepam